Early predictors for late hospitalizations up to 14 years after first episode psychosis.


Journal

Social psychiatry and psychiatric epidemiology
ISSN: 1433-9285
Titre abrégé: Soc Psychiatry Psychiatr Epidemiol
Pays: Germany
ID NLM: 8804358

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 02 06 2020
accepted: 10 11 2020
pubmed: 3 12 2020
medline: 30 7 2021
entrez: 2 12 2020
Statut: ppublish

Résumé

New hospitalizations after first episode psychosis (FEP) may be viewed as an indicator of instability in a psychotic disorder. In the current study we wanted to analyse long term risk for psychosis hospitalizations after FEP. We also wanted to analyse predictors for late hospitalizations, with focus on early antipsychotic medication. First episode psychosis cases were recruited to the Swedish Parachute project in 1996-1997. The program offered highly available and continuous psychosocial support and a cautious use of antipsychotic medication for 5 years from inclusion. Longitudinal data from population registers on psychiatric hospitalizations up to 14 years after inclusion were analysed. One hundred and sixty-one cases were included of the original 175 in the project. Associations with possible early predictive factors from the original project data were analysed with COX regression. A majority of the cases (67%) had hospitalizations in the first year after inclusion in the study. The cohort then diverged into a group (46%) with new hospitalizations for psychosis after the first year, most of them multiple times, and another group (54%) without new hospitalizations for psychosis, many without any late antipsychotic medication. Forty-two percentage of the cases had antipsychotic medication by month 12, and it was significantly associated with later psychosis hospitalizations (HR = 2.5, p value < 0.001). The study demonstrates that a large part of FEP cases have a good outcome as measured by absence of new hospitalizations for psychosis, and that many cases may terminate antipsychotic medication within a year of FEP onset without later relapses needing hospitalizations.

Identifiants

pubmed: 33263822
doi: 10.1007/s00127-020-01991-w
pii: 10.1007/s00127-020-01991-w
pmc: PMC8316245
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1371-1380

Informations de copyright

© 2020. The Author(s).

Références

Curr Opin Psychiatry. 2014 May;27(3):167-72
pubmed: 24662959
Early Interv Psychiatry. 2019 Aug;13(4):902-907
pubmed: 29888512
Psychiatry Res. 2019 Jan;271:374-380
pubmed: 30529874
BMJ. 2006 Jul 29;333(7561):224
pubmed: 16825203
Schizophr Res. 2018 Jul;197:274-280
pubmed: 29274734
Australas Psychiatry. 2016 Aug;24(4):356-9
pubmed: 26906441
J Clin Psychiatry. 2008 Jan;69(1):47-53
pubmed: 18312037
Psychol Med. 2014 Jan;44(1):9-16
pubmed: 23244442
Arch Gen Psychiatry. 1976 Jun;33(6):766-71
pubmed: 938196
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Psychiatr Serv. 2003 Oct;54(10):1407-9
pubmed: 14557530
Nord J Psychiatry. 2006;60(4):286-93
pubmed: 16923637
Schizophr Res. 2011 Dec;133(1-3):36-41
pubmed: 21982098
Schizophr Res. 2018 May;195:231-236
pubmed: 29066258
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:17-54
pubmed: 12650680
Am J Psychiatry. 2018 Aug 1;175(8):765-773
pubmed: 29621900
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Schizophr Res. 2013 Oct;150(1):163-8
pubmed: 23932664
Arch Gen Psychiatry. 2008 Jul;65(7):762-71
pubmed: 18606949
Am J Psychiatry. 2012 Apr;169(4):374-80
pubmed: 22407080
Psychol Med. 1994 Feb;24(1):223-32
pubmed: 8208887
Schizophr Bull. 2015 May;41(3):617-26
pubmed: 25381449
Schizophr Bull. 2013 Nov;39(6):1296-306
pubmed: 23172003
Br J Psychiatry. 2017 Dec;211(6):350-358
pubmed: 28982659
Int J Methods Psychiatr Res. 2007;16(4):208-18
pubmed: 18188834
World Psychiatry. 2018 Jun;17(2):161-162
pubmed: 29856571
Schizophr Bull. 1992;18(2):217-28
pubmed: 1621069
Schizophr Res. 2013 Feb;143(2-3):337-43
pubmed: 23219862
Schizophr Res. 2016 Apr;172(1-3):145-51
pubmed: 26922655
Psychiatry Res. 2014 Feb 28;215(2):274-9
pubmed: 24374114
Arch Gen Psychiatry. 1992 Jul;49(7):538-44
pubmed: 1352677
J Clin Psychiatry. 2010 Jun;71(6):716-28
pubmed: 20573330
Arch Gen Psychiatry. 1999 Mar;56(3):241-7
pubmed: 10078501
Schizophr Res. 2017 Jan;179:50-56
pubmed: 27745754
Acta Psychiatr Scand. 2002 Oct;106(4):276-85
pubmed: 12225494
Psychol Med. 2017 Sep;47(12):2118-2129
pubmed: 28382874
Br J Psychiatry. 2016 Nov;209(5):361-365
pubmed: 27802977
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
Schizophr Bull. 2015 Sep;41(5):1192-203
pubmed: 25995057

Auteurs

Pontus Strålin (P)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Maria Skott (M)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. maria.skott@sll.se.

Johan Cullberg (J)

Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH